Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| JSPR | PRESS-RELEASE | bearish | 8/10 | Jasper Therapeutics announced a comprehensive review of strategic alternatives, including a potential sale, licensing, m | Jun 1, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, sho | Jun 1, 2026 |
| VYGR | 8-K | bullish | 5/10 | Voyager Therapeutics announced FDA clearance of its IND application for VY1706, a tau silencing gene therapy for Alzheim | Jun 1, 2026 |
| NXTC | PRESS-RELEASE | bullish | 7/10 | NextCure announced positive Phase 1 dose escalation data for SIM0505, a CDH6-targeting ADC, at ASCO 2026, showing a 55% | Jun 1, 2026 |
| AAPG | 6-K | neutral | 4/10 | Ascentage Pharma presented positive clinical data for three key drug candidates at ASCO 2026, including first pediatric | Jun 1, 2026 |
| BNTX | 6-K | bullish | 6/10 | BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) pl | Jun 1, 2026 |
| NOTV | 8-K | bearish | 7/10 | Inotiv entered into a Second Supplemental Indenture to extend the grace period for its missed $2.139M interest payment o | Jun 1, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings (ELAB) announced a non-binding LOI to acquire a 76% controlling interest in a privately held precision mac | Jun 1, 2026 |
| CGTX | PRESS-RELEASE | neutral | 2/10 | Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wa | Jun 1, 2026 |
| NTLA | PRESS-RELEASE | neutral | 5/10 | Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be p | Jun 1, 2026 |
| TGTX | PRESS-RELEASE | bullish | 5/10 | TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in Immunology, showing B | Jun 1, 2026 |
| EIKN | 8-K | neutral | 5/10 | Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing | Jun 1, 2026 |
| HCWB | 8-K | bearish | 7/10 | Nasdaq Hearings Panel granted HCW Biologics an extension until July 29, 2026 to regain compliance with the $1 minimum bi | Jun 1, 2026 |
| CABA | DEFA14A | neutral | 3/10 | Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) from the June 9, 2026 | Jun 1, 2026 |
| MOLN | 6-K | neutral | 4/10 | Molecular Partners announced trial-in-progress poster presentations at ASCO and SNMMI 2026 for its lead Radio-DARPin can | Jun 1, 2026 |
| IVVD | PRESS-RELEASE | bullish | 5/10 | Invivyd completed enrollment in the Phase 3 DECLARATION trial evaluating VYD2311 for prevention of symptomatic COVID-19. | Jun 1, 2026 |
| ELOX | 8-K | neutral | 4/10 | Eloxx Pharmaceuticals filed an 8-K detailing a 1-for-11 reverse stock split and authorized share reduction from 500M to | Jun 1, 2026 |
| ELTP | 8-K | neutral | 4/10 | Elite Pharmaceuticals announced it filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagu | Jun 1, 2026 |
| KMDA | 6-K | bullish | 5/10 | Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufa | Jun 1, 2026 |
| SMMT | 8-K | bullish | 7/10 | Summit Therapeutics announced positive Phase III HARMONi-6 overall survival results for ivonescimab in first-line squamo | Jun 1, 2026 |
| INAB | 8-K | bearish | 6/10 | IN8bio entered into an at-the-market (ATM) equity offering agreement with JonesTrading to sell up to $2.8M of common sto | Jun 1, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a Form 6-K on May 30, 2026, solely to announce that its annual Form 20-F for the fiscal year ended Mar | Jun 1, 2026 |
| MLTX | 8-K | neutral | 2/10 | MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and Capacity Agreement with Vetter Pharma | Jun 1, 2026 |
| INAB | 424B5 | bearish | 6/10 | IN8bio filed a 424B5 prospectus supplement establishing an at-the-market (ATM) equity offering facility with JonesTradin | Jun 1, 2026 |
| OGN | PREM14A | bullish | 8/10 | Organon & Co. has filed a preliminary proxy statement (PREM14A) in connection with its proposed acquisition by Sun Pharm | Jun 1, 2026 |
| TKPHF | 6-K | neutral | 2/10 | Takeda filed a shelf registration in Japan for up to JPY 240 billion to issue shares under its Long Term Incentive Plan | Jun 1, 2026 |
| DRMAW | EFFECT | bearish | 6/10 | The SEC declared effective Dermata Therapeutics' S-3 shelf registration (File No. 333-291740) on May 29, 2026, allowing | Jun 1, 2026 |
| XLO | EFFECT | bearish | 5/10 | Xilio Therapeutics' S-3 shelf registration (File No. 333-295785) became effective on May 29, 2026, allowing the company | Jun 1, 2026 |
| AGIO | PRESS-RELEASE | mixed | 6/10 | Agios Pharmaceuticals licensed exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor for immune | Jun 1, 2026 |
| BIIB | PRESS-RELEASE | mixed | 5/10 | Biogen and UCB announced publication of full Phase 3 PHOENYCS GO results for dapirolizumab pegol (DZP) in The Lancet, sh | Jun 1, 2026 |